Shape of the Nations survey and attitudes to cardiometabolic risk

References

• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–7
   Google Scholar
• James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004;11:3–8
   PubMed Web of Science ®Google Scholar
• Smith SC, Haslam D. Abdominal obesity, waist circumference and cardiometabolic risk: awareness among primary care physicians, the general population and patients at risk – the Shape of the Nations survey. Curr Med Res Opin 2007;23:29–47
   PubMed Web of Science ®Google Scholar
• Folsom AR, Kushi LH, Anderson KE, Mink PJ, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women’s Health Study. Arch Intern Med 2000;160:2117–28
   PubMed Web of Science ®Google Scholar
• Kragelund C, Omland T. A farewell to body-mass index? Lancet 2005;366:1589–91
   PubMed Web of Science ®Google Scholar
• Dagenais GR, Yi Q, Mann JF, Bosch J, et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54–60
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, Bautista L, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005;366:1640–9
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Tan CE, Ma S, Wai D, Chew SK, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182–6
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, et al. Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. Heart 2005;91:1003–7
   Google Scholar
• Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. Diabetes Care 2003;26:1380–4
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–62
   Google Scholar
• Antipatis VJ, Kumanyika S, Jeffery RW, Morabia A, et al. Confidence of health professionals in public health approaches to obesity prevention. Int J Obes Relat Metab Disord 1999;23:1004–6
   PubMed Web of Science ®Google Scholar
• Li Z, Maglione M, Tu W, Mojica W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532–46
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N, Hilsted J, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119–25
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389–97
   PubMed Web of Science ®Google Scholar
• Hirschel B. Effect of rimonabant on weight reduction and cardiovascular risk. Lancet 2005;366:369–70
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295: 761–75
   Google Scholar
• Holt R. Orlistat reduces features of the metabolic syndrome: the XENDOS study. Diabetes Obes Metab 2003;5:356
   Web of Science ®Google Scholar
• Maggard MA, Shugarman LR, Suttorp M, Maglione M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142:547–59
   PubMed Web of Science ®Google Scholar
• Loos RJ, Bouchard C. Obesity – is it a genetic disorder? J Intern Med 2003;254:401–25
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP. Beyond LDL-C – the importance of raising HDL-C. Curr Med Res Opin 2002;18:36–44
   PubMed Web of Science ®Google Scholar
• Burchfiel CM, Laws A, Benfante R, Goldberg RJ, et al. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation 1995;92:1430–6
   PubMed Web of Science ®Google Scholar
• Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998;40(Suppl):S3–8
   Google Scholar
• Chapman MJ, Assmann G, Fruchart JC, Shepherd J, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253–68
   PubMed Web of Science ®Google Scholar
• Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139–43
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005;21:299–306
   PubMed Web of Science ®Google Scholar
• Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199–207
   PubMed Web of Science ®Google Scholar
• Nishtar S, Wierzbicki AS, Lumb PJ, Lambert-Hammill M, et al. HDL-cholesterol and waist-hip ratio predict risk of coronary heart disease in Pakistan. Curr Med Res Opin 2004;20:55–62
   Google Scholar
• Chambers JC, Eda S, Bassett P, Karim Y, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001;104:145–50
   PubMed Web of Science ®Google Scholar
• Simmons D, Shaw LM, Scott DJ, Kenealy T, et al. Diabetic nephropathy and microalbuminuria in the community. The South Auckland Diabetes Survey. Diabetes Care 1994;17:1404–10
   PubMed Web of Science ®Google Scholar
• Zimmet PZ, McCarty DJ, de Court. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997;11:60–8
   Google Scholar
• Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N, et al. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J 2005;7:143–7
   Google Scholar
• Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1–10
   PubMed Web of Science ®Google Scholar
• Hergenc G, Schulte H, Assmann G, von EA. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 1999;145:147–56
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, et al. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol 2005;46:380–6
   PubMedGoogle Scholar
• Sattar N, Gaw A, Scherbakova O, Ford I, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–9
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–4
   PubMed Web of Science ®Google Scholar
• Zimmet P, Boyko EJ, Collier GR, de Court. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999;892:25–44
   PubMed Web of Science ®Google Scholar
• Sattar N, Gaw A, Scherbakova O, Ford I, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–9
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211–28
   PubMed Web of Science ®Google Scholar
• Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157–9
   PubMed Web of Science ®Google Scholar
• Hunt KJ, Resendez RG, Williams K, Haffner SM, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251–7
   PubMed Web of Science ®Google Scholar